Cited by 764Cancer-related Molecular PathwaysMultiple and Secondary Primary CancersBRCA gene mutations in cancer

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Bougeard, Gaëlle, Renaux-Petel, Mariette, Flaman, Jean-Michel, Charbonnier, Camille, Fermey, Pierre, Belotti, Muriel, Gauthier-Villars, Marion, Stoppa-Lyonnet, Dominique, Consolino, Emilie, Brugières, Laurence, Caron, Olivier, Benusiglio, Patrick R., Bressac-de Paillerets, Brigitte, Bonadona, Valérie, Bonaïti-Pellié, Catherine, Tinat, Julie, Baert-Desurmont, Stéphanie, Frebourg, Thierry·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2014.59.5728

Open this paper in CoChat — free account

Abstract

Purpose: The aim of the study was to update the description of Li-Fraumeni syndrome (LFS), a remarkable cancer predisposition characterized by extensive clinical heterogeneity. Patients and Methods: From 1,730 French patients suggestive of LFS, we identified 415 mutation carriers in 214 families harboring 133 distinct TP53 alterations and updated their clinical presentation. Results: The 322 affected carriers developed 552 tumors, and 43% had developed multiple malignancies. The mean age of first tumor onset was 24.9 years, 41% having developed a tumor by age 18. In childhood, the LFS tumor spectrum was characterized by osteosarcomas, adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS) observed in 30%, 27%, 26%, and 23% of the patients, respectively. In adults, the tumor distribution was characterized by the predominance of breast carcinomas observed in 79% of the females, and STS observed in 27% of the patients. The TP53 mutation detection rate in children presenting with ACC or choroid plexus carcinomas, and in females with breast cancer before age 31 years, without additional features indicative of LFS, was 45%, 42% and 6%, respectively. The mean age of tumor onset was statistically different (P < .05) between carriers harboring dominant-negative missense mutations (21.3 years) and those with all types of loss of function mutations (28.5 years) or genomic rearrangements (35.8 years). Affected children, except those with ACC, harbored mostly dominant-negative missense mutations. Conclusion: The clinical gradient of the germline TP53 mutations, which should be validated by other studies, suggests that it might be appropriate to stratify the clinical management of LFS according to the class of the mutation.

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.5728

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“Dominant-negative mutations were defined on the basis of the ability of the mutant protein to inhibit the activity of the wild-type p53 protein,(16) as indicated in the International Agency for Research on Cancer TP53 Database.(17)”
Method
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms
Li, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,514
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Hagman, K. D. F., Noltner, K., Buzin, C. H., Gu, D., Wen, C. Y., Nguyen, V. Q., Han, J., Lowstuter, K. J., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 607
Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.8.606 · Cited by 553

Show all 42 references

Research works printed but not linked: 3

Li FP, 1988, Cancer Res, 48, 5358
Nutting C, 2000, Clin Oncol (R Coll Radiol), 12, 300
Spencer SJ, 1999, J Clin Endocrinol Metab, 84, 1110

Sorted by citations

Items 401–500 of 764

Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li–Fraumeni syndrome
Ono, T., Yoshimatsu, Y., Noguchi, R., Sin, Y., Tsuchiya, R., Akiyama, T. E., Sugaya, J., Fukushima, S., Kojima, N., Yoshida, A., et al. (2022) · Human Cell · doi:10.1007/s13577-022-00671-y · Cited by 5
Pediatric pituitary adenoma and medulloblastoma in the setting of p53 mutation: case report and review of the literature
Birk, H., Kandregula, S., Cuevas-Ocampo, A. K., Wang, C. J., Kosty, J. A., & Notarianni, C. (2022) · Child s Nervous System · doi:10.1007/s00381-022-05478-8 · Cited by 5
Alkylating agents are possible inducers of glioblastoma and other brain tumors
Smith, C. J., Perfetti, T. A., Chokshi, C., Venugopal, C., Ashford, J. W., & Singh, S. K. (2024) · Human & Experimental Toxicology · doi:10.1177/09603271241256598 · Cited by 5
Evaluation of TP53 Pro72Arg and MDM2 SNP285–SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations
Ponti, F., Corsini, S., Gnoli, M., Pedrini, E., Mordenti, M., & Sangiorgi, L. (2016) · Familial Cancer · doi:10.1007/s10689-016-9895-3 · Cited by 5
A rare case of multiple cutaneous melanomas in Li‐Fraumeni syndrome: A coincidental association or a component of the syndrome?
Akay, B. N., Heper, A. O., Topçu, V., & Farabi, B. (2019) · Australasian Journal of Dermatology · doi:10.1111/ajd.13012 · Cited by 5
Differences in patient ascertainment affect the use of gene‐specified ACMG/AMP phenotype‐related variant classification criteria: Evidence for TP53
Fortuño, C., Pesaran, T. F., Dolinsky, J. S., Yussuf, A., McGoldrick, K., Goldgar, D. E., James, P. A., & Spurdle, A. B. (2020) · Human Mutation · doi:10.1002/humu.23972 · Cited by 5
Urgent need to recognize that disease-causing TP53 variants with atypical penetrance require distinct clinical recommendations
Kratz, C. P., Frone, M. N., Khincha, P. P., Hatton, J. N., Penkert, J., James, P., Spurdle, A. B., & Fortuño, C. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag015 · Cited by 4
Simultaneous Detection of 2 Types of Malignancies in a Pediatric Patient on FDG PET/CT Led to Diagnosis of Li-Fraumeni Syndrome
Kan, Y., Si, Y., Wang, W., & Yang, J. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004266 · Cited by 4
Opportunistic genetic screening increases the diagnostic yield and is medically valuable for care of patients and their relatives with hereditary cancer
Fernández‐Castillejo, S., Roig, B., Melé, M., Serrano, S., Salvat, M., Querol, M., Brunet, J., Pineda, M., Cisneros, A., Parada, D., et al. (2023) · Journal of Medical Genetics · doi:10.1136/jmg-2023-109389 · Cited by 4
Bone sarcomas and cancer predisposition syndromes
Tlemsani, C., Bougeard, G., Gauthier‐Villars, M., Denizeau, P., Winter, S., Michot, C., Baujat, G., Paillerets, B. B., de Beaumais, T. A., Rouchaud, A., et al. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2024.10.014 · Cited by 4
Self-citation
Undifferentiated Pleomorphic Sarcoma in Children and Young Adults: A Comprehensive Clinicopathologic, Genomic, and Epigenetic Comparison With Adult Counterparts
Saoud, C., Gundem, G., Vanderbilt, C., Wexler, L. H., Reed, D. R., Tap, W. D., Singer, S., Villafania, L. B., Papaemmanouil, E., Benhamida, J. K., et al. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100769 · Cited by 4
Familial Thyroid Cancers Syndromes
Pishdad, R., Barbesino, G., & Wirth, L. J. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2025.03.018 · Cited by 4
Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories
Kasper, E., Boulouard, F., Basset, N., Golmard, L., Sassi, H., Bouvignies, E., Branchaud, M., Charbonnier, C., Parodi, N., Rolain, M., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.35475 · Cited by 4
Self-citation
High-Penetrance Rare Variants Underlying Familial Lung Cancer Risk: Insights From Genetic Epidemiology of Lung Cancer Consortium
Liu, Y., Li, Y., Byun, J., Shaw, V. R., Pikielny, C. W., Peng, B., Cheng, C., Tsavachidis, S., Xiao, X., Zhu, D. K., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.12.004 · Cited by 4
Syndrome mit breitem Tumorspektrum
Steinke‐Lange, V., Becker, K., Behnecke, A., Neuhann, T., & Holinski‐Feder, E. (2017) · Medizinische Genetik · doi:10.1007/s11825-017-0154-2 · Cited by 4
Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies
Atajanova, T., Rahman, M. M., Konieczkowski, D. J., & Morris, Z. S. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03532-1 · Cited by 4
Genetic Predisposition to Sarcoma: What Should Clinicians Know?
Vagher, J., Mehrhoff, C. J., Florou, V., & Maese, L. D. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01192-6 · Cited by 4
Les cancers héréditaires du sein vus par le pathologiste
Vincent‐Salomon, A., Bataillon, G., & Djerroudi, L. (2020) · Annales de Pathologie · doi:10.1016/j.annpat.2020.02.023 · Cited by 4
Co-occurrence of rhabdomyosarcoma and Mowat–Wilson syndrome: is there a connection?
Rogač, M., Kitanovski, L., & Writzl, K. (2017) · Clinical Dysmorphology · doi:10.1097/mcd.0000000000000174 · Cited by 4
Revisiting multiple erroneous genetic testing results and clinical misinterpretations in a patient with Li-Fraumeni syndrome: lessons for translational medicine
Sokolova, T. N., Breder, V. V., Shumskaya, I. S., Suspitsin, E. N., Алексахина, С. Н., Yanus, G. A., Tiurin, V. I., Ivantsov, A. O., Vona, B., Раскин, Г. А., et al. (2021) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-020-00157-8 · Cited by 4
Genetic testing in patients with triple-negative or hereditary breast cancer
Bernstein‐Molho, R., Evron, E., Yerushalmi, R., & Paluch–Shimon, S. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000784 · Cited by 4
TP53 Pathogenic Variants in Early-Onset Breast Cancer Patients Fulfilling Hereditary Breast and Ovary Cancer and Li-Fraumeni-like Syndromes
da Silva, P. F. F., Goveia, R. M., Teixeira, T. B., Gamba, B. F., de Lima, A. P., Rogatto, S. R., & Silveira-Lacerda, E. D. P. (2022) · Biomolecules · doi:10.3390/biom12050640 · Cited by 4
GENETIC PREDISPOSITION TO HEMATOLOGIC MALIGNANCIES IN CHILDHOOD AND ADOLESCENCE
Fabozzi, F., & Mastronuzzi, A. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.032 · Cited by 5
Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis
Reinig, E. F., Rubinstein, J. D., Patil, A. T., Schussman, A. L., Horner, V. L., Kanagal‐Shamanna, R., Churpek, J. E., & Matson, D. R. (2023) · Leukemia · doi:10.1038/s41375-023-01955-4 · Cited by 4
Functional pri-miR-34b/c rs4938723 and KRAS 3′UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
Vieira, I. A., Pezzi, E. H., Bandeira, I. C., Reis, L. B., Rocha, Y. M. D. A., Fernandes, B., Siebert, M., Miyamoto, K. N., Siqueira, M., Achatz, M. I., et al. (2023) · Gene · doi:10.1016/j.gene.2023.148069 · Cited by 4
LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations
Nguyen, N. H., Dodd-Eaton, E. B., Peng, G., Corredor, J. L., Jiao, W., Woodman-Ross, J., Arun, B., & Wang, W. (2024) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00167 · Cited by 4
Papillary Thyroid Carcinoma, Cushing Disease, and Adrenocortical Carcinoma in a Patient with Li-Fraumeni Syndrome
Friedman, J. G., & Papagiannis, I. G. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.03.007 · Cited by 4
TP53 p.R337H Germline Variant among Women at Risk of Hereditary Breast Cancer in a Public Health System of Midwest Brazil
Correa, T. S., Asprino, P. F., de Oliveira, E. S. C., Leite, A. C. R., Weis, L. N., Achatz, M. I., de Oliveira, C. P., Sandoval, R. L., & Barroso‐Sousa, R. (2024) · Genes · doi:10.3390/genes15070928 · Cited by 4
Composite Adrenocortical Carcinoma and Neuroblastoma in an Infant With a TP53 Germline Mutation: A Case Report and Literature Review
Tang, Y., Yu, T., Ma, J., Zhou, Y., Xu, M., & Gao, Y. (2018) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001205 · Cited by 4
Adrenal tumors: when to search for a germline abnormality?
Gimenez‐Roqueplo, A. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000525 · Cited by 4
Is CHEK2 a moderate-risk breast cancer gene or the younger sister of Li-Fraumeni?
Silva, D. L. D., & Winship, I. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-236435 · Cited by 4
Factors Affecting Genetic Consultation in Adolescent and Young Adult Patients With Sarcoma
McKay, G. E., Zakas, A. L., Osman, F., & Parkes, A. M. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7034 · Cited by 4
When tissue is not the only issue: Poorly differentiated lung squamous-cell carcinoma with adrenal, costochondral, and cardiac metastases – case report
Clark, M., Griborio-Guzman, A. G., Burute, N., Lubbers, S., Anthes, M., Sadreddini, M., & Aseyev, O. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1117024 · Cited by 4
Diagnosis and Management of Hereditary Sarcoma
Thomas, D. M., & Ballinger, M. L. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-29998-3_10 · Cited by 4
Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma
Shaul, E., Roth, M. E., Lo, Y., Geller, D. S., Hoang, B. H., Yang, R., Malkin, D. M., Gorlick, R. G., & Gill, J. B. (2018) · Cancer · doi:10.1002/cncr.31212 · Cited by 4
The function of a heterozygous p53 mutation in a Li-Fraumeni syndrome patient
Li, Y., Li, T., Tang, Y., Zhan, Z., Ding, L., Song, L., Yu, T., Yang, Y., Ma, J., Zhang, Y., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234262 · Cited by 4
Metabolic permissiveness: how tissue context shapes cancerPreprint
Moschandrea, C., & Frezza, C. (2026) · Genes & Development · doi:10.1101/gad.353516.125 · Cited by 4
Novel germline TP53 variant (p.(Phe109Ile)) confers high risk of cancer
Byrjalsen, A., Stoltze, U. K., Lautrup, C. K., Christensen, L. L., Mikkelsen, T. S., Hjalgrim, L. L., Brok, J. S., Dahl, C., Schmiegelow, K., Borgwardt, L., et al. (2024) · Journal of Medical Genetics · doi:10.1136/jmg-2024-110255 · Cited by 4
Early-onset Colorectal Cancer in a Patient with Li-Fraumeni Syndrome: A Case Series and Literature Review
Sekiguchi, K., Motoo, I., Ando, T., Noguchi, A., Fukuda, R., Nomura, K. T., Nakayama, Y., Kajiura, S., Ueda, Y., Goto, Y., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.4945-24 · Cited by 3
Optimizing shared decision-making for risk-reducing mastectomy in women with Li–Fraumeni syndrome using patient-reported outcome measures
Polidorio, N., Sandoval, R. L., Bioni, P., Pisani, J. P., & Achatz, M. I. (2025) · Scientific Reports · doi:10.1038/s41598-025-89068-z · Cited by 3
Characteristics predicting reduced penetrance variants in the high-risk cancer predisposition gene TP53
Fortuño, C., Richardson, M. E., Pesaran, T. F., McGoldrick, K., James, P. A., & Spurdle, A. B. (2025) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2025.100484 · Cited by 3
In-frame germline TP53 variant impairs p53 oligomerization and predisposes to cancer
Vanikova, L., Macháčková, E., Němcová, B., Soukupová, J., Petrezsélyová, S., Novakova, K., Ženatová, M., Pavlová, Š., Kleiblová, P., Kleibl, Z., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-14684-8 · Cited by 3
Germline predispositions to myeloid malignancies: Across the lifespan
Atluri, H., Swaroop, A., & Godley, L. A. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.08.002 · Cited by 3
RNF207 promotes the proliferation, migration and invasion of osteosarcoma through KCNQ1 mediated activation of ERK/MEK signaling pathway
Liu, W., Xia, K., Tong, K., Huang, X., Wei, Z., Wei, Z., & Guo, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115482 · Cited by 3
A comprehensive framework for the management of hereditary breast cancers: guiding light in precision medicine
Ekram, S. N., & AlEissa, M. M. (2025) · Oncology Reviews · doi:10.3389/or.2025.1633387 · Cited by 3
Cancer Predisposition Syndromes With Involvement of the Head and Neck Regions in Children: An Imaging Guide
Mertiri, L., Desai, N. K., Lequin, M. H., Mertiri, D., Tran, H., Alves, C., Chiocchi, M., Huisman, T. A. G. M., & D’Arco, F. (2025) · Journal of Neuroimaging · doi:10.1111/jon.70092 · Cited by 3
Prospective Study of Annual Whole-Body Magnetic Resonance Imaging as Part of a Multimodality Screening Program for Individuals With Li-Fraumeni Syndrome
Maoz, A., Chen, N., Umaretiya, P. J., Cahill, S. R., Schwartz, A., Jagannathan, J. P., Voss, S. D., Friedman, D. N., Walsh, M. F., Robson, M. E., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00264 · Cited by 3
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome
Montellier, E., Manches, O., Gaucher, J., Freyçon, C., Hoyos, D. B. C., Blanchet, S., Verboom, M., Dutzmann, C. M., Coutant, S., Bou, J., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.106065 · Cited by 4
Self-citation
Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome
Oba, L., Best, A. F., Mai, P. L., Achatz, M. I., Albert, P. S., Savage, S. A., & Khincha, P. P. (2021) · Familial Cancer · doi:10.1007/s10689-021-00265-x · Cited by 3
Combinatorial batching of DNA for ultralow-cost detection of pathogenic variants
Stoltze, U. K., Hagen, C. M., Hansen, T. V. O., Byrjalsen, A., Gerdes, A., Yakimov, V., Rasmussen, S., Bækvad‐Hansen, M., HOUGAARD, D. M., Schmiegelow, K., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01167-6 · Cited by 3
Hematologic malignancies in Li–Fraumeni syndrome: A case report
Bundrant, B., Gerstein, Y. S., Arun, B. K., & Dinardo, C. D. (2024) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.63573 · Cited by 3
Genetic Testing of Breast Cancer Patients with Very Early-Onset Breast Cancer (≤30 Years) Yields a High Rate of Germline Pathogenic Variants, Mainly in the BRCA1, TP53, and BRCA2 Genes
Apostolou, P., Dellatola, V., Παπαθανασίου, Α., Kalfakakou, D., Fountzilas, E., Tryfonopoulos, D. J., Karageorgopoulou, S., Yannoukakos, D., Konstantopoulou, I., & Fostira, F. (2024) · Cancers · doi:10.3390/cancers16132368 · Cited by 3
What Is the Cost: Financial Toxicity and Screening Fatigue in Li–Fraumeni Syndrome
Underkofler, K. A., Thomas, M. H., Erickson, S. H., Panzer, A. A., Fitzgibbon, K. S., & Ring, K. L. (2024) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-24-0184 · Cited by 3
The Importance of Genetic Screening on the Syndromes of Colorectal Cancer and Gastric Cancer: A 2024 Update
Lupan, I., Silaghi, C. N., Stroe, C., Muntean, I. A., Deleanu, D. M., Bintintan, V. V., & Samaşcă, G. (2024) · Biomedicines · doi:10.3390/biomedicines12122655 · Cited by 3
Adjuvant Radiotherapy and Breast Cancer in Patients with Li-Fraumeni Syndrome: A Critical Review
Shrebati, A., Loap, P., & Kirova, Y. (2025) · Cancers · doi:10.3390/cancers17071206 · Cited by 3
Syndromes associated with abnormalities in the adrenal cortex
Chen, C., & Hunt, J. L. (2017) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2017.06.003 · Cited by 3
Epithelioid Angiomyolipoma in a Patient With Li-Fraumeni Syndrome: Rare Pathologic Diagnosis
Jasim, S., Tamboli, P., Lee, S. C., Strong, L. C., Elsayes, K. M., Ayala‐Ramirez, M., & Habra, M. A. (2015) · AACE Clinical Case Reports · doi:10.4158/ep15957.cr · Cited by 3
Clinical Implications of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome in the Era of Genomic Medicine: Clinician’s Perspectives
Park, H. S., Park, J. S., Nam, E. J., Lee, S., Han, J. W., & Kim, T. I. (2016) · Journal of Breast Disease · doi:10.14449/jbd.2016.4.1.1 · Cited by 3
Genitourinary manifestations of hereditary cancer predisposition syndromes in children
Gillespie, N. J., & Mater, D. V. (2020) · Translational Andrology and Urology · doi:10.21037/tau-2019-pum-09 · Cited by 3
Germ Cell Mosaicism: A Rare Cause of Li-Fraumeni Recurrence Among Siblings
Donovan, L. N., Kohlmann, W. K., Snow, A. K., Neklason, D. W., Schiffman, J. D., & Maese, L. D. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00064 · Cited by 3
Three Primary Tumors Including EGFR-mutated Non–Small Cell Lung Cancer as First Presentation in Patient With Li-Fraumeni Syndrome
Gower, A., Kim, J. K., Spector, K., Menashe, D., Vail, E., & Natale, R. B. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.09.006 · Cited by 3
Hereditary Breast Cancer: BRCA and Other Susceptibility Genes
Azzollini, J., Fontana, L., & Manoukian, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-41207-4_3 · Cited by 3
A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk
Yu, Y., Chang, K., Chen, J., Bohlender, R. J., Fowler, J., Zhang, D., Huang, M., Chang, P., Li, Y., Wong, J., et al. (2021) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100078 · Cited by 3
Presentation, diagnosis, and management of the Li-Fraumeni syndrome
Ogden, J. R., & Pippen, J. (2022) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2022.2071100 · Cited by 3
Hepatoblastoma with bone/bone marrow metastasis in Li‐Fraumeni syndrome patient
Hasegawa, M., Sugiyama, M., Terashita, Y., Cho, Y., & Manabe, A. (2022) · Pediatrics International · doi:10.1111/ped.15135 · Cited by 3
Frequency of germline genetic variants in women with a personal or family history of breast cancer from Brazil
Pereira, J. Z., Carneiro, J. G., Vieira, M. S., Valente, B. M., de Oliveira, P. Z., Mello, C. L., de Campos, C. L. V., & Gomes, K. B. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07840-0 · Cited by 3
Gastric Cancer: A Practical Review on Management of Individuals with Hereditary or Familial Risk for Gastric Cancer
Linhares, M., Pinto, C. M. M., Libânio, D., Teixeira, M. R., Dinis-Ribeiro, M. J., & Brandão, C. (2022) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000527208 · Cited by 3
The Role of Radiation Therapy in Locally Advanced Breast Cancer in a Patient With Li-Fraumeni Syndrome
Roberts, A. C., Lunt, L. G., Coogan, A. C., & Madrigrano, A. (2022) · The American Surgeon · doi:10.1177/00031348221135780 · Cited by 3
A matched case-control study of the prognosis of early breast cancer in patients with Li-Fraumeni syndrome (BREAST TP53)
Petry, V., Bonadio, R. C., Testa, L., Cohn, D. J. B. H., Cagnacci, A. Q. C., Campos, R., Fragoso, M. C. B. V., & Estevez-Diz, M. D. P. (2023) · The Breast · doi:10.1016/j.breast.2023.02.002 · Cited by 3
Management of pulmonary nodules in women with pregnant intention: A review with perspective
Zhang, J., Tang, K., Liu, L., Guo, C., Zhao, K., & Li, S. (2023) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_270_22 · Cited by 3
Lessons learnt from the clinico-genomic profiling of families with Li Fraumeni syndrome at a tertiary care centre in North India
Tansir, G., Rastogi, S., Dubasi, S., Chitikela, S., Lavu, R. R., Barwad, A. W., & Goyal, A. (2023) · ecancermedicalscience · doi:10.3332/ecancer.2023.1550 · Cited by 3
Clinical Features of Li-Fraumeni Syndrome in Korea
Song, R., Kong, S., Choi, W., Lee, E., Woo, J., Han, J. H., Lee, S., Kang, H., & Jung, S. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.794 · Cited by 3
Current prospects of hereditary adrenal tumors: towards better clinical management
Ohmoto, A., Hayashi, N., Takahashi, S., & Ueki, A. (2024) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-024-00276-6 · Cited by 4
Targeted sequencing for hereditary breast and ovarian cancer in BRCA1/2-negative families reveals complex genetic architecture and phenocopies
Plowman, J. N., Matoy, E. J., Uppala, L. V., Draves, S. B., Watson, C. J., Sefranek, B. A., Stacey, M. L., Anderson, S. P., Belshan, M., Blue, E., et al. (2024) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2024.100306 · Cited by 4
Germline Predisposition in Hematologic Malignancies
Kansal, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00126-8 · Cited by 3
Li-Fraumeni syndrome: a germline TP53 splice variant reveals a novel physiological alternative transcript
Louis, J., Rolain, M., Levacher, C., Baudry, K., Pujol, P., Ruminy, P., Baert‐Desurmont, S., Bou, J., Bouvignies, E., Coutant, S., et al. (2025) · Journal of Medical Genetics · doi:10.1136/jmg-2024-110449 · Cited by 2
Self-citation
Clinical Sequence Revealed the Prevalence and Biological Significance of Somatic Pathogenic Variants in Thoracic Cancer: Implications for Germline Status
Fukushima, T., Nakamura, K., Terai, H., Ohgino, K., Kawano, R., Ishikawa, M., Emoto, K., Takaoka, H., Saito, A., Ito, F., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.03.012 · Cited by 3
Germline large genomic alterations on 7q in patients with multiple primary cancers
Villacis, R. A. R., Basso, T. R., do Canto, L. M., de Nóbrega, A. F., Achatz, M. I., & Rogatto, S. R. (2017) · Scientific Reports · doi:10.1038/srep41677 · Cited by 3
Les femmes à haut risque de cancer du sein : quelle attitude ?
Livon, D., Moretta, J., & Noguès, C. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.07.014 · Cited by 3
Imaging of Children with Cancer Predisposition Syndromes
Anupindi, S. A., Smith, E. A., & Chauvin, N. A. (2019) · Pediatric oncology · doi:10.1007/978-3-030-03777-2_20 · Cited by 3
Prédisposition héréditaire au cancer du sein (2)
Cohen‐Haguenauer, O. (2019) · médecine/sciences · doi:10.1051/medsci/2019072 · Cited by 3
FANCA, TP53, and del(5q)/RPS14 alterations in a patient with T-cell non-Hodgkin lymphoma and concomitant Fanconi anemia and Li-Fraumeni syndrome
Errichiello, E., Mina, T., Morbini, P., Zecca, M., & Zuffardi, O. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.10.003 · Cited by 3
Reviewing the occurrence of large genomic rearrangements in patients with inherited cancer predisposing syndromes: importance of a comprehensive molecular diagnosis
Rocha, D. L., Ashton‐Prolla, P., & Rosset, C. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2049247 · Cited by 3
Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations
Azzollini, J., Mariani, M., Peissel, B., & Manoukian, S. (2017) · Familial Cancer · doi:10.1007/s10689-017-0020-z · Cited by 3
Re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243–50
Sassi, H., Caron, O., & Rouleau, É. (2022) · European Urology · doi:10.1016/j.eururo.2022.07.038 · Cited by 3
Self-citation
Missense but mis-spliced: germline TP53 variant c.671A>C (p.E224A) and the path from uncertainty to pathogenicityPreprint
Velkova, I., Cappato, S., Rivera, D., Romano, F., Schonneger, D., Bocciardi, R., Hainaut, P. L., Marco, P. D., Gismondi, V., Cirmena, G., et al. (2025) · medRxiv · doi:10.1101/2025.07.31.25332437 · Cited by 3
Radiotherapy in patients with breast cancer and Li-Fraumeni syndrome — a narrative review
Huszno, J., Rutkowski, T. W., Roch-Zniszczoł, A., & Stec, R. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.98107 · Cited by 2
Evaluation of whole-body MRI for cancer early detection in Li-Fraumeni syndrome
Sodde, P., Hyder, Z., Pugh, S., Lalloo, F. I., Martin, R., Soh, C., Naqvi, J., Whitehouse, R. W., Evans, D. G., & Woodward, E. R. (2025) · Journal of Medical Genetics · doi:10.1136/jmg-2025-110704 · Cited by 2
Melittin inhibits osteosarcoma growth in vitro and in vivo by inactivating the Wnt/β-catenin signaling pathway
Wang, X., Chang, J., Sun, X., Guo, S., Li, Y., Shi, Q. W., & Yang, Y. (2025) · Journal of Cancer · doi:10.7150/jca.109750 · Cited by 2
Rate of germline pathogenic sequence variants in cancer susceptibility genes in an Israeli pediatric and adolescent cancer cohort: a single institute experience
Nahom, D., Frenkel, Z., Toren, A., Friedman, E., & Kventsel, I. (2025) · Familial Cancer · doi:10.1007/s10689-025-00489-1 · Cited by 2
Fusion-Negative Rhabdomyosarcoma: Clinical Application of Targeted RNA Sequencing
Glembocki, A. I., Siddaway, R., Arnoldo, A., & Somers, G. R. (2025) · Pediatric and Developmental Pathology · doi:10.1177/10935266251370493 · Cited by 2
Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification
Jansche, R., Heitmeir, B., Faust, U., Pospiech, H., Sutter, C., Albig, C., Hennig, F., Janni, W., Schmutzler, R., Hauke, J., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08463-0 · Cited by 2
Tumor patterns and cancer risk in carriers of TP53 exonic germline variants that alter mRNA splicing
Schönegger, D., Montellier, E., Blanchet, S., Freyçon, C., Monti, P., Goudie, C., Bougeard, G., Kratz, C. P., Hainaut, P. L., & Reymer, A. (2026) · European Journal of Human Genetics · doi:10.1038/s41431-026-02061-6 · Cited by 2
Self-citation
Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores
Evans, D. G., Woodward, E. R., Howell, S. J., Verhoef, S., Howell, A., & Lalloo, F. I. (2016) · Familial Cancer · doi:10.1007/s10689-016-9942-0 · Cited by 2
The Role of Genetic Mutations in the Prevention of Malignant Tumours in a Healthy Population (A Review)
Lipatov, O. N., & Тагировна, А. К. (2021) · Creative Surgery and Oncology · doi:10.24060/2076-3093-2020-10-4-330-338 · Cited by 2
A Retrospective 5-Year Single Center Study Highlighting the Risk of Cancer Predisposition in Adolescents and Young Adults
Jordan, F. A., Huber, S., Sommer, S., Schenkirsch, G., Frühwald, M. C., Trepel, M., Claus, R., & Kuhlen, M. (2021) · Cancers · doi:10.3390/cancers13123033 · Cited by 2
Li-Fraumeni Syndrome
Villani, A., Frébourg, T., & Malkin, D. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-74448-9_1 · Cited by 2
Features of heritable TP53-related cancer syndrome
Stepanov, I., Vasilyeva, E., Соколенко, А. П., & Имянитов, Е. Н. (2022) · Voprosy Onkologii · doi:10.37469/0507-3758-2022-68-2-140-148 · Cited by 2
Li–Fraumeni Syndrome ☆
Michaeli, O., & Malkin, D. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.96122-1 · Cited by 2
Secondary findings in prenatal exome sequencing: Ethical and counseling challenges
Yang, Y., & Li, D. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.06.002 · Cited by 2

Authors: Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., Caron, O., Benusiglio, P. R., Bressac-de Paillerets, B., Bonadona, V., Bonaïti-Pellié, C., Tinat, J., Baert-Desurmont, S., & Frebourg, T.
Affiliations: Inserm (FR)
Gaëlle Bougeard, Mariette Renaux-Petel, Jean-Michel Flaman, Camille Charbonnier, Pierre Fermey, Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, Institut National de la Santé et de la Recherche Médicale (Inserm) U1079, University of Rouen, Institute for Research and Innovation in Biomedicine; Julie Tinat, Stéphanie Baert-Desurmont, Thierry Frebourg, University Hospital, Rouen; Muriel Belotti, Marion Gauthier-Villars, Dominique Stoppa-Lyonnet, Curie Institute, Paris; Emilie Consolino, Laurence...
ORCID: Bougeard, Gaëlle
Flaman, Jean-Michel
Charbonnier, Camille
Brugières, Laurence
Caron, Olivier
Benusiglio, Patrick R.
Bonadona, Valérie
Tinat, Julie
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-07-20
Volume: 33
Issue: 21
Pages: 2345-2352
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2014.59.5728
OpenAlex: W2095770043
Cited by: 760
References: 42
Citations by year: 2026: 68 · 2025: 85 · 2024: 95 · 2023: 67 · 2022: 82 · 2021: 81 · 2020: 78 · 2019: 59 · 2018: 42 · 2017: 64 · 2016: 30 · 2015: 9
FWCI: 21.11
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: Li-Fraumeni syndrome, germline TP53 mutation, cancer susceptibility, multiple primary neoplasms, childhood tumors, osteosarcoma, adrenocortical carcinoma, choroid plexus carcinoma, breast cancer, soft tissue sarcoma, central nervous system tumors, loss-of-function mutations, genome rearrangement, mutation classification
MeSH terms: Adolescent, Adult, Female, France, Genetic Testing, Genotype, Humans, Male, Phenotype, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Sequence Analysis, DNA, Age of Onset, Germ-Line Mutation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks